Warum fällt Sarepta Therapeutics Inc-Aktie (SRPT)?
SRPT's stock fell 7.93% as some analysts voiced concerns that upcoming confirmatory trial data for its gene therapy to treat Duchenne muscular dystrophy (DMD) may not be enough to secure approval for expanded use.
Before the market opened on Thursday, shares of Sarepta Therapeutics (NASDAQ: SRPT) experienced a decline of roughly 10% in pre-market trading. This drop occurred following a report stating that the U.S. Food and Drug Administration (FDA) staff had a leaning towards rejecting the company's Duchenne muscular dystrophy gene therapy, but a senior official intervened.
Sarepta Therapeutics's stock is going down today after the announcement of an advisory meeting for the SRP-9001's development (the first gene therapy) with the FDA, since their gene therapy isn't believed to be beneficial. The meeting comes as the company was preparing for the SRP-9001 regulatory action date on May 29, 2023.